ABBV-CLS-484: A Novel Oral PTPN2/1 Inhibitor for Cancer Immunotherapy (KCRS 2026) - Jun 12, 2026 - Abstract #16; Pres time: Jul 24, 2026; 03:45 PM - 04:25 PM; P1 | "Methods M20-431 is a first-in-human Phase 1 clinical trial testing the safety and preliminary clinical activity of ABBV-CLS-484 alone and with pembrolizumab in patients with advanced solid tumors whose disease has progressed on standard therapies (NCT04777994). In tandem with these clinical cohorts, additional strategies that combine ABBV-CLS-484 with VEGF TKIs, CAR-T therapy, and T cell engagers are being tested in preclinical models. Keywords Phase 1 trial, immunotherapy, PTPN2/2 inhibitor, PD-1 blockade"
First-in-human • IO biomarker • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Solid Tumor • PTPN2
|
|
Hans Hammers MD PhD 1, 2; Emiliano Calvo MD PhD 3; Benedito A. Carneiro MD 4; Michael R. Harrison MD 5; Eric Jonasch MD 6; David Braun MD PhD 7; Do-Youn Oh MD PhD 8; Kartik Seghal MD 9; Ulka Vaishampayan MD 10; Noboru Yamamoto MD 11; Leisha A. Emens MD PhD 12; Jie Tang MS 12; Anh Nguyen PharmD 12; Nidhi Prem MD 12; Damian Trujillo PhD 12; Cathleen Hartman PhD 12; Marcia Paddock MD PhD 12; Jonathan Powell MD PhD 12; David McDermott MD 13
|